Hemodynamics in the isolated cirrhotic liver
- PMID: 17975473
- DOI: 10.1097/MCG.0b013e318150d3b5
Hemodynamics in the isolated cirrhotic liver
Abstract
Increased intrahepatic resistance is the initial event to the increased portal pressure and development portal hypertension in cirrhosis. Narrowing of the sinusoids due to anatomic changes is the main component of the increased intrahepatic resistance. However, a dynamic component is also involved in the increased vascular tone in cirrhosis. The imbalance between the hyperresponsiveness and overproduction of vasoconstrictors (mainly endothelin-1 and cyclooxygenase-derived prostaglandins) and the hyporesponsiveness and impaired production of vasodilators [mainly nitric oxide (NO)] are the mechanisms responsible of the increased vascular tone in the sinusoidal/postsinusoidal area. In contrast, the vascular resistance in the hepatic artery, which is determined in the presinusoidal area, is decreased due to increased vasodilators (NO and adenosine). This suggests different availabilities of NO in the intrahepatic circulation with preserved production in the presinusoidal area and impaired production in the sinusoidal/postsinusoidal area.
Similar articles
-
Pathophysiology of portal hypertension.J Physiol Pharmacol. 2008 Aug;59 Suppl 2:231-8. J Physiol Pharmacol. 2008. PMID: 18812641 Review.
-
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.Gastroenterology. 2007 Feb;132(2):709-19. doi: 10.1053/j.gastro.2006.12.041. Epub 2006 Dec 20. Gastroenterology. 2007. PMID: 17258737
-
Vascular deterioration in cirrhosis: the big picture.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S247-53. doi: 10.1097/MCG.0b013e3181572357. J Clin Gastroenterol. 2007. PMID: 17975472 Review.
-
Molecular mechanisms of increased intrahepatic resistance in portal hypertension.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S259-61. doi: 10.1097/MCG.0b013e318150d0e1. J Clin Gastroenterol. 2007. PMID: 17975474 Review.
-
Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future--Georges Brohée Lecture.Acta Gastroenterol Belg. 2009 Jan-Mar;72(1):9-16. Acta Gastroenterol Belg. 2009. PMID: 19402365
Cited by
-
Predictors and Outcomes of Post-transjugular Intrahepatic Portosystemic Shunt Liver Failure in Patients with Cirrhosis.Dig Dis Sci. 2024 Mar;69(3):1025-1034. doi: 10.1007/s10620-023-08256-x. Epub 2024 Feb 10. Dig Dis Sci. 2024. PMID: 38341393
-
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension.Gastroenterol Res Pract. 2017;2017:3943210. doi: 10.1155/2017/3943210. Epub 2017 Aug 10. Gastroenterol Res Pract. 2017. PMID: 28855918 Free PMC article.
-
Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.BMC Gastroenterol. 2009 Sep 18;9:69. doi: 10.1186/1471-230X-9-69. BMC Gastroenterol. 2009. PMID: 19765284 Free PMC article.
-
Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.World J Gastroenterol. 2017 Apr 14;23(14):2613-2624. doi: 10.3748/wjg.v23.i14.2613. World J Gastroenterol. 2017. PMID: 28465646 Free PMC article.
-
Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition.Hepatology. 2009 Jan;49(1):185-94. doi: 10.1002/hep.22589. Hepatology. 2009. PMID: 18844235 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical